1. Home
  2. PLBY vs RLYB Comparison

PLBY vs RLYB Comparison

Compare PLBY & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

N/A

Current Price

$1.13

Market Cap

151.0M

ML Signal

N/A

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$17.02

Market Cap

89.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
RLYB
Founded
1953
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.0M
89.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PLBY
RLYB
Price
$1.13
$17.02
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
406.9K
8.0K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
N/A
EPS
N/A
6.16
Revenue
$120,928,000.00
$858,000.00
Revenue This Year
$9.17
N/A
Revenue Next Year
$7.10
N/A
P/E Ratio
N/A
$2.80
Revenue Growth
4.13
43.00
52 Week Low
$1.08
$0.48
52 Week High
$2.75
$17.57

Technical Indicators

Market Signals
Indicator
PLBY
RLYB
Relative Strength Index (RSI) 38.93 46.40
Support Level $1.09 $16.51
Resistance Level $1.30 $17.32
Average True Range (ATR) 0.04 0.42
MACD -0.01 -0.05
Stochastic Oscillator 4.17 1.32

Price Performance

Historical Comparison
PLBY
RLYB

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: